BACKGROUND: Current ancillary markers for diagnosis in prostate biopsies include p63 and alpha-methylacyl-CoA racemase (AMACR). Annexin II (ANXII), a calcium and phospholipid binding protein, is lost in prostate cancer. AIMS: To investigate ANXII expression in order to assess its utility as a novel diagnostic marker in comparison to p63 and AMACR. METHODS: Using immunohistochemistry on six tissue microarrays, ANXII, p63, and AMACR expression was analysed from 210 radical prostatectomy cases. Staining was evaluated in benign and atrophic glands, high-grade prostatic intraepithelial neoplasia (HGPIN), and prostatic adenocarcinoma. Separate scores were given for ANXII, AMACR and p63 expression. RESULTS: Diffuse cytoplasmic expression of ANXII correlated with p63 reactivity in basal cells. Benign glands were positive for ANXII in 286/292 cores (98%) and negative for AMACR in all 292 cores. HGPIN showed heterogeneous expression of AMACR and ANXII. A significantly larger proportion of HGPIN glands were correctly identified as ANXII negative than as positive for AMACR. ANXII loss in prostate cancer was found in 282/320 cores (88%) and correlated with positive AMACR expression (272/320 cores, 85%), which was not statistically significant. There was no statistically significant correlation between ANXII scores and the clinical parameters examined. CONCLUSIONS: Immunohistochemical staining for ANXII is a consistent and reliable marker of prostatic neoplasia. The findings of this study suggest the potential utility of ANXII as a diagnostic aid in prostate cancer histopathology.
BACKGROUND: Current ancillary markers for diagnosis in prostate biopsies include p63 and alpha-methylacyl-CoA racemase (AMACR). Annexin II (ANXII), a calcium and phospholipid binding protein, is lost in prostate cancer. AIMS: To investigate ANXII expression in order to assess its utility as a novel diagnostic marker in comparison to p63 and AMACR. METHODS: Using immunohistochemistry on six tissue microarrays, ANXII, p63, and AMACR expression was analysed from 210 radical prostatectomy cases. Staining was evaluated in benign and atrophic glands, high-grade prostatic intraepithelial neoplasia (HGPIN), and prostatic adenocarcinoma. Separate scores were given for ANXII, AMACR and p63 expression. RESULTS: Diffuse cytoplasmic expression of ANXII correlated with p63 reactivity in basal cells. Benign glands were positive for ANXII in 286/292 cores (98%) and negative for AMACR in all 292 cores. HGPIN showed heterogeneous expression of AMACR and ANXII. A significantly larger proportion of HGPIN glands were correctly identified as ANXII negative than as positive for AMACR. ANXII loss in prostate cancer was found in 282/320 cores (88%) and correlated with positive AMACR expression (272/320 cores, 85%), which was not statistically significant. There was no statistically significant correlation between ANXII scores and the clinical parameters examined. CONCLUSIONS: Immunohistochemical staining for ANXII is a consistent and reliable marker of prostatic neoplasia. The findings of this study suggest the potential utility of ANXII as a diagnostic aid in prostate cancer histopathology.
Authors: Gladell P Paner; John R Srigley; Anuradha Radhakrishnan; Cynthia Cohen; Brian F Skinnider; Satish K Tickoo; Andrew N Young; Mahul B Amin Journal: Am J Surg Pathol Date: 2006-01 Impact factor: 6.394
Authors: U Zimmermann; C Woenckhaus; S Pietschmann; H Junker; S Maile; K Schultz; C Protzel; J Giebel Journal: Virchows Arch Date: 2004-08-26 Impact factor: 4.064
Authors: Z Jiang; C L Wu; B A Woda; K A Iczkowski; P G Chu; M S Tretiakova; R H Young; L M Weiss; R D Blute; C B Brendler; T Krausz; J C Xu; K L Rock; M B Amin; X J Yang Journal: Histopathology Date: 2004-09 Impact factor: 5.087
Authors: Gavin D Richardson; Craig N Robson; Shona H Lang; David E Neal; Norman J Maitland; Anne T Collins Journal: J Cell Sci Date: 2004-06-29 Impact factor: 5.285
Authors: Mathew T Mizwicki; June E Bishop; Christopher J Olivera; Johanna Huhtakangas; Anthony W Norman Journal: J Cell Biochem Date: 2004-03-01 Impact factor: 4.429
Authors: Chin-Lee Wu; Ximing J Yang; Maria Tretiakova; Kurt T Patton; Elkan F Halpern; Bruce A Woda; Robert H Young; Zhong Jiang Journal: Hum Pathol Date: 2004-08 Impact factor: 3.466
Authors: Abhijit G Banerjee; Jie Liu; Yawei Yuan; Velliyur K Gopalakrishnan; Sonny L Johansson; Amit K Dinda; Narmada P Gupta; Lindsey Trevino; Jamboor K Vishwanatha Journal: Mol Cancer Date: 2003-10-08 Impact factor: 27.401
Authors: Nicholas B Griner; Denise Young; Pankaj Chaudhary; Ahmed A Mohamed; Wei Huang; Yongmei Chen; Taduru Sreenath; Albert Dobi; Gyorgy Petrovics; Jamboor K Vishwanatha; Isabell A Sesterhenn; Shiv Srivastava; Shyh-Han Tan Journal: Mol Cancer Res Date: 2014-10-24 Impact factor: 5.852